MedTrace Logo

Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

NCT05373680 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2025-08-14

No results posted yet for this study

Summary

This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.

Conditions

  • Renal Insufficiency, Chronic

Interventions

DRUG

Metformin

Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

DRUG

Empagliflozin

Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

OTHER

Control

Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Sponsors & Collaborators

  • Mansoura University

    collaborator OTHER

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-04-01
Completion
2024-04-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05373680 on ClinicalTrials.gov